FibroGen (Mexico) Performance
| FGEN Stock | MXN 140.41 21.59 13.33% |
The firm shows a Beta (market volatility) of 0.24, which means not very significant fluctuations relative to the market. As returns on the market increase, FibroGen's returns are expected to increase less than the market. However, during the bear market, the loss of holding FibroGen is expected to be smaller as well. At this point, FibroGen has a negative expected return of -0.53%. Please make sure to confirm FibroGen's standard deviation, information ratio, and the relationship between the coefficient of variation and variance , to decide if FibroGen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days FibroGen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 678.4 M | |
| Total Cashflows From Investing Activities | -427 M |
FibroGen |
FibroGen Relative Risk vs. Return Landscape
If you would invest 19,900 in FibroGen on November 5, 2025 and sell it today you would lose (5,859) from holding FibroGen or give up 29.44% of portfolio value over 90 days. FibroGen is generating negative expected returns and assumes 3.0527% volatility on return distribution over the 90 days horizon. Simply put, 27% of stocks are less volatile than FibroGen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
FibroGen Target Price Odds to finish over Current Price
The tendency of FibroGen Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 140.41 | 90 days | 140.41 | about 92.64 |
Based on a normal probability distribution, the odds of FibroGen to move above the current price in 90 days from now is about 92.64 (This FibroGen probability density function shows the probability of FibroGen Stock to fall within a particular range of prices over 90 days) .
FibroGen Price Density |
| Price |
Predictive Modules for FibroGen
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as FibroGen. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.FibroGen Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. FibroGen is not an exception. The market had few large corrections towards the FibroGen's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold FibroGen, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of FibroGen within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.51 | |
β | Beta against Dow Jones | 0.24 | |
σ | Overall volatility | 17.53 | |
Ir | Information ratio | -0.19 |
FibroGen Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of FibroGen for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for FibroGen can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| FibroGen generated a negative expected return over the last 90 days | |
| FibroGen has high historical volatility and very poor performance | |
| The company reported the revenue of 235.31 M. Net Loss for the year was (290.02 M) with loss before overhead, payroll, taxes, and interest of (104.61 M). | |
| FibroGen has accumulated about 565.4 M in cash with (82.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.56. | |
| Over 79.0% of the company shares are owned by institutional investors |
FibroGen Fundamentals Growth
FibroGen Stock prices reflect investors' perceptions of the future prospects and financial health of FibroGen, and FibroGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FibroGen Stock performance.
| Return On Equity | -1.85 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (2.94) % | |||
| Operating Margin | (2.52) % | |||
| Current Valuation | 21.87 B | |||
| Shares Outstanding | 93.96 M | |||
| Price To Book | 54.45 X | |||
| Price To Sales | 231.63 X | |||
| Revenue | 235.31 M | |||
| EBITDA | (288.53 M) | |||
| Cash And Equivalents | 565.4 M | |||
| Cash Per Share | 6.56 X | |||
| Total Debt | 77.14 M | |||
| Debt To Equity | 15.10 % | |||
| Book Value Per Share | 0.28 X | |||
| Cash Flow From Operations | (82.23 M) | |||
| Earnings Per Share | (62.14) X | |||
| Total Asset | 773.82 M | |||
About FibroGen Performance
Evaluating FibroGen's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if FibroGen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if FibroGen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is headquartered in San Francisco, California. FibroGen operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 461 people.Things to note about FibroGen performance evaluation
Checking the ongoing alerts about FibroGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FibroGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FibroGen generated a negative expected return over the last 90 days | |
| FibroGen has high historical volatility and very poor performance | |
| The company reported the revenue of 235.31 M. Net Loss for the year was (290.02 M) with loss before overhead, payroll, taxes, and interest of (104.61 M). | |
| FibroGen has accumulated about 565.4 M in cash with (82.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.56. | |
| Over 79.0% of the company shares are owned by institutional investors |
- Analyzing FibroGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FibroGen's stock is overvalued or undervalued compared to its peers.
- Examining FibroGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FibroGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of FibroGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FibroGen's stock. These opinions can provide insight into FibroGen's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for FibroGen Stock Analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.